U.S. markets closed

Aclaris Therapeutics, Inc. (ACRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.29+0.13 (+0.72%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close18.16
Open17.88
Bid17.81 x 1200
Ask18.99 x 1100
Day's Range17.88 - 18.33
52 Week Range1.41 - 30.38
Volume637,393
Avg. Volume706,614
Market Cap1.082B
Beta (5Y Monthly)0.65
PE Ratio (TTM)N/A
EPS (TTM)-1.43
Earnings DateAug 05, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Aclaris Announces Pricing of Public Offering of Common Stock
    GlobeNewswire

    Aclaris Announces Pricing of Public Offering of Common Stock

    WAYNE, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 7,042,254 shares of its common stock at a price to the public of $17.75 per share. In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 1,056,338 additional shares of common stock at the pub

  • Aclaris (ACRS) Announces Data on Atopic Dermatitis Candidate
    Zacks

    Aclaris (ACRS) Announces Data on Atopic Dermatitis Candidate

    Aclaris (ACRS) reports encouraging preliminary top-line results from a phase IIa study evaluating its JAK 1/3 inhibitor, ATI-1777, for the treatment of moderate to severe atopic dermatitis.

  • Aclaris Announces Proposed Public Offering of Common Stock
    GlobeNewswire

    Aclaris Announces Proposed Public Offering of Common Stock

    WAYNE, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it intends to offer and sell, subject to market conditions, $75 million in shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Aclaris. Aclaris also intends to grant the underwri